NYR -Brain Injury Program GLP Studies Further Update 5
Nyrada Inc (ASX: NYR) have released an announcement updating the market on the Good Laboratory Practice (GLP) studies. The latest… Read more
Nyrada Inc Investor Presentation September 2024
› Drug discovery and development company specialising in rational design of novel small molecule therapeutics. › Nyrada’s lead drug candidate… Read more
Nyrada Inc – Brain Injury Program GLP Studies Further Update 4
Highlights: •Completed dog cardiovascular study provides ongoing data to support safety and tolerability of Nyrada’s lead Brain Injury drug candidate… Read more
Nyrada Inc – Annual Report
“Our lead brain injury program candidate, NYR-BI03, is targeting a very large and growing market. There are no current FDA-approved… Read more
Nyrada Inc – Brain Injury Program GLP Studies Further Update #3
Highlights: •Completed rat respiratory study provides additional data to support safety and tolerability of Nyrada’s lead Brain Injury drug candidate…. Read more
Nyrada Inc- Investor Presentation August
Improving Lives, Offering Hope
Nyrada Inc Update on GLP Studies
Nyrada Inc. released an update on the Good Laboratory Practice (GLP) studies being conducted on the company’s drug candidate to… Read more
Nyrada Inc – Brain Injury Program GLP Studies Further Update #2
Highlights: •Additional study provided further data to support safety and tolerability of Nyrada’s lead Brain Injury drug candidate. •Rat CNS… Read more
Nyrada GLP Studies Update
Highlights: •Two key safety studies have provided data to support safety and tolerability of Nyrada’s lead Brain Injury drug candidate… Read more
